NASDAQ:CLSD Clearside Biomedical (CLSD) Stock Price, News & Analysis → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Free CLSD Stock Alerts $1.34 -0.03 (-2.19%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$1.29▼$1.4550-Day Range$1.15▼$2.0252-Week Range$0.65▼$2.12Volume201,248 shsAverage Volume339,988 shsMarket Capitalization$100.12 millionP/E RatioN/ADividend YieldN/APrice Target$4.75 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Clearside Biomedical alerts: Email Address Clearside Biomedical MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside254.5% Upside$4.75 Price TargetShort InterestHealthy0.30% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 2 Articles This WeekInsider TradingAcquiring Shares$656,387 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.56) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.85 out of 5 starsMedical Sector390th out of 909 stocksPharmaceutical Preparations Industry175th out of 423 stocks 3.5 Analyst's Opinion Consensus RatingClearside Biomedical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageClearside Biomedical has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.30% of the outstanding shares of Clearside Biomedical have been sold short.Short Interest Ratio / Days to CoverClearside Biomedical has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Clearside Biomedical has recently decreased by 34.01%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldClearside Biomedical does not currently pay a dividend.Dividend GrowthClearside Biomedical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CLSD. Previous Next 1.9 News and Social Media Coverage News SentimentClearside Biomedical has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Clearside Biomedical this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for CLSD on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Clearside Biomedical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Clearside Biomedical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $656,387.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.80% of the stock of Clearside Biomedical is held by insiders.Percentage Held by InstitutionsOnly 18.75% of the stock of Clearside Biomedical is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Clearside Biomedical are expected to grow in the coming year, from ($0.56) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Clearside Biomedical is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Clearside Biomedical is -2.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe harsh reality of the stock marketOK, you’re not supposed to say this In fact, maverick investor Graham Lindman says it’s become the silent elephant in the room that everyone is pretending isn’t there. But he just said it: Most stocks suck. And he isn’t saying that figuratively or subjectively… You see, 96% of stocks underperform. Just 4% of “Apex Stocks” generate virtually all the wealth.All you have to do is watch here for all the details. About Clearside Biomedical Stock (NASDAQ:CLSD)Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.Read More CLSD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CLSD Stock News HeadlinesApril 21, 2024 | seekingalpha.comCLSD Clearside Biomedical, Inc.April 17, 2024 | americanbankingnews.comClearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of "Buy" by AnalystsApril 24, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 16, 2024 | globenewswire.comClearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of DirectorsApril 2, 2024 | globenewswire.comClearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 18, 2024 | globenewswire.comClearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical OfficerMarch 14, 2024 | markets.businessinsider.comClearside Biomedical: Strong Buy Rating on Robust Financials and Clinical Trial ProgressMarch 14, 2024 | finance.yahoo.comClearside Biomedical Full Year 2023 Earnings: Revenues Beat Expectations, EPS In LineApril 24, 2024 | Wall Street Star (Ad)This Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.March 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Clearside Biomedical on Innovative Treatments and Strong FinancialsMarch 13, 2024 | finance.yahoo.comClearside Biomedical, Inc. (NASDAQ:CLSD) Q4 2023 Earnings Call TranscriptMarch 12, 2024 | benzinga.comClearside Biomedical: Q4 Earnings InsightsMarch 12, 2024 | finance.yahoo.comClearside Biomedical Inc (CLSD) Reports Significant Licensing Revenue Growth in Q4 and Full ...March 12, 2024 | globenewswire.comClearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateMarch 11, 2024 | benzinga.comPreview: Clearside Biomedical's EarningsMarch 1, 2024 | finance.yahoo.comClearside Biomedical, Inc. (CLSD)February 29, 2024 | globenewswire.comClearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024February 25, 2024 | investorplace.com7 Biotech Penny Stocks on the Verge of Clinical Trial VictoryFebruary 21, 2024 | markets.businessinsider.comModivCare is about to announce its earnings — here's what Wall Street expectsFebruary 21, 2024 | benzinga.comClearside Biomedical Stock (NASDAQ:CLSD), Short Interest ReportFebruary 18, 2024 | finance.yahoo.comCLSD Apr 2024 5.000 callFebruary 9, 2024 | msn.comClearside Biomedical Launches $15M Direct OfferingFebruary 9, 2024 | msn.comClearside Biomedical Announces Registered Direct Offering PricingFebruary 9, 2024 | finance.yahoo.comPleasing Signs As A Number Of Insiders Buy Clearside Biomedical StockFebruary 7, 2024 | finance.yahoo.comClearside Biomedical Announces Pricing of $15 Million Registered Direct OfferingDecember 15, 2023 | markets.businessinsider.comBuy Rating Affirmed for Clearside Biomedical Amidst Strong Clinical Progress and Strategic PartnershipsDecember 14, 2023 | finanznachrichten.deClearside Biomedical, Inc.: Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMDSee More Headlines Receive CLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Clearside Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/12/2024Today4/24/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CLSD CUSIPN/A CIK1539029 Webwww.clearsidebio.com Phone(678) 270-3631Fax678-270-4033Employees30Year FoundedN/APrice Target and Rating Average Stock Price Target$4.75 High Stock Price Target$6.00 Low Stock Price Target$4.00 Potential Upside/Downside+249.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-32,490,000.00 Net Margins-394.91% Pretax Margin-394.91% Return on EquityN/A Return on Assets-85.31% Debt Debt-to-Equity RatioN/A Current Ratio4.42 Quick Ratio4.42 Sales & Book Value Annual Sales$8.23 million Price / Sales12.35 Cash FlowN/A Price / Cash FlowN/A Book Value($0.25) per share Price / Book-5.44Miscellaneous Outstanding Shares74,720,000Free Float67,398,000Market Cap$101.62 million OptionableOptionable Beta2.29 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. George M. Lasezkay J.D. (Age 72)Pharm.D., Pharma.D., President, CEO & Director Comp: $816.4kMr. Charles A. Deignan (Age 60)Chief Financial Officer Comp: $536.95kDr. Thomas A. Ciulla M.B.A. (Age 59)M.D., Chairman of Scientific Advisory Board Comp: $597.21kMs. Jenny R. Kobin (Age 57)Head of Investor Relations Mr. Rick McElhenyVice President of Corporate DevelopmentMr. Rafael V. Andino (Age 59)Senior Vice President of Engineering & Manufacturing Ms. Susan L. Coultas Ph.D.Chief Clinical OfficerDr. Ngai Hang Chong M.B.A.M.D., Chief Medical OfficerMr. Leslie B. Zacks (Age 55)Secretary More ExecutivesKey CompetitorsBarinthus BiotherapeuticsNASDAQ:BRNSEliem TherapeuticsNASDAQ:ELYMCellectar BiosciencesNASDAQ:CLRBFibroGenNASDAQ:FGENVaccitechNASDAQ:VACCView All CompetitorsInsiders & InstitutionsAnthony S GibneyBought 6,710 shares on 4/17/2024Total: $8,387.50 ($1.25/share)International Assets Investment Management LLCBought 36,000 shares on 4/11/2024Ownership: 0.048%Ngai Hang Victor ChongBought 30,000 shares on 3/20/2024Total: $48,000.00 ($1.60/share)Bradford T WhitmoreBought 444,444 shares on 2/7/2024Total: $599,999.40 ($1.35/share)Simplex Trading LLCBought 2,100 shares on 2/2/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions CLSD Stock Analysis - Frequently Asked Questions Should I buy or sell Clearside Biomedical stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Clearside Biomedical in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLSD shares. View CLSD analyst ratings or view top-rated stocks. What is Clearside Biomedical's stock price target for 2024? 4 brokerages have issued 12 month price targets for Clearside Biomedical's shares. Their CLSD share price targets range from $4.00 to $6.00. On average, they predict the company's stock price to reach $4.75 in the next twelve months. This suggests a possible upside of 254.5% from the stock's current price. View analysts price targets for CLSD or view top-rated stocks among Wall Street analysts. How have CLSD shares performed in 2024? Clearside Biomedical's stock was trading at $1.17 on January 1st, 2024. Since then, CLSD shares have increased by 14.5% and is now trading at $1.34. View the best growth stocks for 2024 here. Are investors shorting Clearside Biomedical? Clearside Biomedical saw a drop in short interest in the month of March. As of March 31st, there was short interest totaling 224,300 shares, a drop of 34.0% from the March 15th total of 339,900 shares. Based on an average trading volume of 353,400 shares, the short-interest ratio is presently 0.6 days. View Clearside Biomedical's Short Interest. When is Clearside Biomedical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our CLSD earnings forecast. How were Clearside Biomedical's earnings last quarter? Clearside Biomedical, Inc. (NASDAQ:CLSD) released its earnings results on Tuesday, March, 12th. The company reported ($0.08) earnings per share for the quarter, beating analysts' consensus estimates of ($0.10) by $0.02. The business earned $6.35 million during the quarter, compared to analysts' expectations of $3.40 million. What other stocks do shareholders of Clearside Biomedical own? Based on aggregate information from My MarketBeat watchlists, some companies that other Clearside Biomedical investors own include Northwest Biotherapeutics (NWBO), Ocular Therapeutix (OCUL), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Melinta Therapeutics (MLNT), Organigram (OGI), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Miragen Therapeutics (MGEN) and Gran Tierra Energy (GTE). When did Clearside Biomedical IPO? Clearside Biomedical (CLSD) raised $50 million in an initial public offering on Thursday, June 2nd 2016. The company issued 7,200,000 shares at $7.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and Needham & Company, Wedbush PacGrow was co-manager. Who are Clearside Biomedical's major shareholders? Clearside Biomedical's stock is owned by a variety of institutional and retail investors. Top institutional investors include International Assets Investment Management LLC (0.05%). Insiders that own company stock include Anthony S Gibney, Bradford T Whitmore, Bradford T Whitmore, Charles A Deignan, Clay Thorp, George M Lasezkay, Nancy J Hutson, Ngai Hang Victor Chong, Richard T Burke and Thomas Ciulla. View institutional ownership trends. How do I buy shares of Clearside Biomedical? Shares of CLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CLSD) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressPentagon contract could send this $2 AI stock soaringBehind the MarketsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Clearside Biomedical, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
